Advances in Cell Based Assays, 11th & 12th November 2014, London UK

LONDON, LONDON, UNITED KINGDOM, August 27, 2014 /EINPresswire.com/ -- Angiocrine Bioscience announced in a press release last week that it has licensed the rights to a new technology developed by a team of researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College. This scientific advance, reported in the July 2 issue of Nature, could potentially lead to therapies for patients with blood disorders from their own cells.

“This technology nicely complements our efforts in applying our VeraVec™ platform to the expansion of umbilical cord blood stem cells, another approach toward making stem cell transplant safer and more broadly available to patients in need, ” said Geoff Davis, Angiocrine’s CEO.* Source http://www.digitaljournal.com/pr/2136364

Hear more from Angiocrine Bioscience at Advances in Cell Based Assays this autumn as Director of Research, Dr Daniel Nolan, provides further insights into the VeraVec™ platform.

The talk will discuss recent works demonstrating how the chemoresistant niche within cancer involves the vasculature, a look into how the vascular stem cell niche is capable of expanding stem cells in vitro while maintaining potency and engraftability, plus VeraVec™ amenability to 3D and co-culture assays for screening purposes.

Other Speakers Include:

# Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK
# Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D
# Dr Lesley Jenkinson, Scientist 1, MedImmune
# Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
# Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh
# Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma
# Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono
# Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis

For further details and to secure a place at Advances in Cell Based Assays, visit www.cellbasedassay.co.uk

7th annual conference:
Advances in Cell Based Assays
11th & 12th November 2014
Marriott Regents Park Hotel, London UK
www.cellbasedassay.co.uk

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world?s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.